Ronald C. Renaud
Independent Chairman of the BoardMr. Ronald C. Renaud, Jr. also known as Ron, Jr., M.B.A., serves as President, Chief Executive Officer and Director at Kailera Therapeutics, Inc. since September 2024. He is Director of Cardurion Pharmaceuticals, Inc. from September 2024. Mr. Renaud is President and CEO at Cerevel Therapeutics Holdings, Inc. since June 12, 2023 and its Director from June 12, 2023 until August 1, 2024. He served as Managing Director at Bain Capital Life Sciences Investors, LLC since October 2022 till 2023. He served as Chairman of the Board at Ikena Oncology, Inc. until January 2023. He joined the firm in 2022. He serves as Director at Jnana Therapeutics Inc. since November 15, 2022. He serves as the Independent Chairman of Board of Directors at Upstream Bio Inc. since November 2021. He was the Chief Executive Officer of Translate Bio, Inc. since November 2014 until September 2021 and served as its Interim Principal Financial Officer since December 27, 2020. Under his leadership as CEO, he led Translate Bio from an early-stage startup to a public company with a leading mRNA technology platform, substantially growing the size and value of the organization through innovative dealmaking and strategic growth opportunities. As the Idenix Pharmaceuticals CEO, he streamlined operations and established a promising portfolio of potential treatments for hepatitis C. He served as President at Translate Bio, Inc. since November 2014 until March 22, 2021. He had been Chairman of the Board at Ikena Oncology, Inc. since March 2018 and served as its Director since 2017 until December 15, 2022. He served as Non-Executive Chairman at Atara Biotherapeutics, Inc. since April 2020 until December 2022. He has done prior work in evaluating, building and leading biotechnology companies, with deep expertise in executive leadership, finance and operations. His career underscores his commitment to delivering new treatment options to patients in need, cultivating strong company cultures and advancing innovation in challenging disease areas. He serves as an Atlas Advisor at Atlas Venture Advisors, Inc. He served as a Principal and Equity Research Analyst of SoundView Technology Group, Inc. since September 2003. He served as the Chief Executive Officer and President of Idenix Pharmaceuticals Inc. from October 28, 2010, to August 5, 2014. He served as the Chief Financial Officer of Idenix Pharmaceuticals Inc., from June 29, 2007, to October 28, 2010, served as its Chief Business Officer from June 2010 to October 28, 2010 and also served as its Principal Accounting Officer. He served as Chief Financial Officer, Senior Vice President, Secretary and Treasurer of Keryx Biopharmaceuticals Inc. from February 16, 2006, to June 27, 2007 and also served as its Principal Accounting Officer until June 27, 2007. He was a senior research Analyst and global sector coordinator for JP Morgan Securities from May 2004 to February 2006, where he was responsible for the biotechnology equity research effort, covering all ranges of capitalized biotechnology companies. He served as Biotechnology Equity Research Analyst at JP Morgan and Bear Stearns. He served as Investor a Biotechnology equity Analyst for investment banks such as Bear Stearns and Schwab SoundView Capital Markets, Research Division from 2000 to 2006. He held various roles at Amgen as well as at the Dana-Farber Cancer Institute. He had been a Director of Translate Bio, Inc. since November 2014 until September 2021. He served as a Director of Chimerix, Inc. since December 17, 2014, until June 11, 2020. He was Director at Axial Therapeutics, Inc. since April 2017 until February 2023 and also served as its Chairman until 2023. He was an Independent Director of Akebia Therapeutics, Inc. since September 2014 until December 12, 2018. He served as a Director of PTC Therapeutics, Inc. from June 11, 2014, to May 16, 2017. He holds a B.A. from Saint Anselm College in Manchester, NH and an M.B.A. from the Marshall School of Business at the University of Southern California.
Positions
- Company NameUpstream Bio, Inc.Stock CodeUPBPositionIndependent Chairman of the BoardColleagues
- ERE. Rand SutherlandCEO & Director
- RCRonald C. RenaudIndependent Chairman of the Board
- MPMichael Paul GrayCFO & COO
- ADAaron DeykinChief Medical Officer and Head of Research & Development
- SPStacy PriceChief Technology Officer
- MBMeggan BuckwellDirector of Corporate Communications & Investor Relations
- MKMarcella Kuhlman RuddyIndependent Director
- DBDaniella BeckmanIndependent Director
- ECErez ChimovitsIndependent Director
- Company NameKailera Therapeutics, Inc.Stock CodeKLRAPositionPresident, CEO & DirectorColleagues
- JFJohn F. MilliganIndependent Non-Employee Chairman
- PDPaul Douglas BurgessChief Operating & Business Officer
- JBJamie Beth ColemanChief Commercial Officer
- DWDouglas W. PaganChief Financial Officer
- MGMaura GavaghanVice President of Corporate Communications & Investor Relations
- ATAndrew T. KaplanIndependent Non-Employee Director
- CHChristopher HiteIndependent Non-Employee Director
- FKFranklin K. ClyburnIndependent Non-Employee Director
